Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair regrowth using a chewable combination of oral minoxidil and finasteride without side effects, unlike when taken separately. The treatment is from Hims, and the user is satisfied with the progress, especially on the crown.

A satirical discussion on intentionally inducing hair loss using harmful habits and substances like cigarettes, junk food, anabolic steroids, and stress. The conversation humorously suggests extreme measures like chemotherapy and hydrofluoric acid, while also mentioning the ineffectiveness of sulfates and pumpkin seed oil in hair loss prevention.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

The conversation is about someone wanting to import RU58841 or CB-03-01 from China for hair loss treatment but being concerned about receiving counterfeit products. Specific treatments mentioned are RU58841 and CB-03-01.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.

The conversation is about obtaining alfatradiol in Canada, specifically in Quebec, and whether it requires a prescription or can be bought online. A user suggests ordering it from a specific website.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Hair loss, Minoxidil, finasteride, and RU58841 as potential treatments for it.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

Users discuss alternatives to DHT blockers for hair loss, suggesting minoxidil, microneedling, natural DHT blockers, and scalp massages. Some explore RU58841, ketoconazole, hair transplants, and hair systems due to side effects from finasteride and dutasteride.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

User discusses using trichosol as a vehicle for hair loss treatments like finasteride and minoxidil. They ask about others' experiences and the stability of the solutions.

Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

The conversation discusses the effectiveness of DHT blockers for hair loss, questioning if they are just vitamins or truly effective. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The post is about the potential legal trouble of bringing a four-month supply of fluridil, a hair loss treatment, into non-Western countries.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.